LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes - Full Text View

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00214630

Purpose

Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes

Condition	Intervention	Phase
Acute Coronary Syndromes	Drug: rosuvastatin calcium Drug: atorvastatin	Phase III

Drug Information available for: Atorvastatin Atorvastatin calcium Rosuvastatin Rosuvastatin calcium Calcium gluconate

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	A 12-Week Randomized, Open-Label 3-Arm, Parallel Group, Multicenter Phase IIIb Study Comparing Efficacy and Safety of Rosuvastatin 20mg and 40mg With That of Atorvastatin 80 mg in Subjects With Acute Coronary Syndromes

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Secondary Outcome Measures:

% change from baseline in LDL-C following 2 & 6 weeks of treatment; % change from baseline in TC, HDL-C, triglycerides, non-HDL-C, apolipoprotein A-1, apolipoprotein B, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, ApoB/Apo A-1 @ weeks 6 & 12

Enrollment:	825
Study Start Date:	September 2003
Study Completion Date:	November 2007
Primary Completion Date:	August 2007 (Final data collection date for primary outcome measure)

Eligibility

Criteria

Inclusion Criteria:

Non-ST segment elevation ACS and ST segment elevation ACS who receive optimal reperfusion therapy

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00214630

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

AstraZeneca Crestor Medical Science Director, MD

AstraZeneca

More Information

Publications indexed to this study:

Study ID Numbers:	4522US/0001, D3560L00021, LUNAR
Study First Received:	September 21, 2005
Last Updated:	January 25, 2008
ClinicalTrials.gov Identifier:	NCT00214630
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Calcium, Dietary
Rosuvastatin
Heart Diseases
Myocardial Ischemia

Acute Coronary Syndrome
Vascular Diseases
Ischemia
Atorvastatin

Additional relevant MeSH terms:

Antimetabolites
Pathologic Processes
Disease
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Antilipemic Agents

Syndrome
Enzyme Inhibitors
Cardiovascular Diseases
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009